Next Article in Journal / Special Issue
Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions
Previous Article in Journal
Androgen Receptor Signaling in Salivary Gland Cancer
Previous Article in Special Issue
Interstitial Photodynamic Therapy—A Focused Review
Article Menu
Issue 2 (February) cover image

Export Article

Open AccessArticle
Cancers 2017, 9(2), 18; doi:10.3390/cancers9020018

Photodynamic Synergistic Effect of Pheophorbide a and Doxorubicin in Combined Treatment against Tumoral Cells

1
Institut Químic de Sarrià, Universitat Ramon Llull, Via Augusta 390, 08017 Barcelona, Spain
2
Departamento de Biología, Facultad de Ciencias, Universidad Autónoma de Madrid, Darwin 2, 28049 Cantoblanco-Madrid, Spain
*
Authors to whom correspondence should be addressed.
Academic Editor: Michael R. Hamblin
Received: 8 November 2016 / Revised: 20 January 2017 / Accepted: 11 February 2017 / Published: 17 February 2017
(This article belongs to the Special Issue Photodynamic Cancer Therapy)
View Full-Text   |   Download PDF [10830 KB, uploaded 20 February 2017]   |  

Abstract

A combination of therapies to treat cancer malignancies is at the forefront of research with the aim to reduce drug doses (ultimately side effects) and diminish the possibility of resistance emergence given the multitarget strategy. With this goal in mind, in the present study, we report the combination between the chemotherapeutic drug doxorubicin (DOXO) and the photosensitizing agent pheophorbide a (PhA) to inactivate HeLa cells. Photophysical studies revealed that DOXO can quench the excited states of PhA, detracting from its photosensitizing ability. DOXO can itself photosensitize the production of singlet oxygen; however, this is largely suppressed when bound to DNA. Photodynamic treatments of cells incubated with DOXO and PhA led to different outcomes depending on the concentrations and administration protocols, ranging from antagonistic to synergic for the same concentrations. Taken together, the results indicate that an appropriate combination of DOXO with PhA and red light may produce improved cytotoxicity with a smaller dose of the chemotherapeutic drug, as a result of the different subcellular localization, targets and mode of action of the two agents. View Full-Text
Keywords: photodynamic therapy; doxorubicin; pheophorbide a; synergic treatment; HeLa cells photodynamic therapy; doxorubicin; pheophorbide a; synergic treatment; HeLa cells
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Ruiz-González, R.; Milán, P.; Bresolí-Obach, R.; Stockert, J.C.; Villanueva, A.; Cañete, M.; Nonell, S. Photodynamic Synergistic Effect of Pheophorbide a and Doxorubicin in Combined Treatment against Tumoral Cells. Cancers 2017, 9, 18.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top